<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02687932</url>
  </required_header>
  <id_info>
    <org_study_id>2015-0938</org_study_id>
    <nct_id>NCT02687932</nct_id>
  </id_info>
  <brief_title>Pharmacological Reduction of Functional, Ischemic Mitral REgurgitation</brief_title>
  <acronym>PRIME</acronym>
  <official_title>Multicenter, Randomized, Double-blind, Active-controlled Study to Assess the Efficacy of LCZ696 Compared to Valsartan on Reduction of Mitral Regurgitation in Patients With Left Ventricular Dysfunction and Secondary Functional Mitral Regurgitation of Stage B and C</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Functional MR is caused by adverse left ventricular remodeling after myocardial injury and
      associated with an increased incidence of heart failure and death. Because secondary
      functional MR usually develops as a result of LV dysfunction, diuretics, beta blockers,
      angiotensin-converting-enzyme (ACE) inhibitors or angiotensin receptor blockers (ARB), and
      aldosterone antagonists are given to patients with functional MR in line with the guidelines
      in the management of heart failure. However, functional MR appears to remain common despite
      use of these drugs and current medical treatment is usually insufficient for reducing MR or
      reversing the adverse LV remodeling. As LCZ696 is a dual-acting inhibitor of the
      renin-angiotensin-aldosterone system (RAAS) and neutral endopeptidase (NEP), LCZ696 has
      greater hemodynamic and neurohormonal effects than ARB alone. Investigators try to examine
      the hypothesis that LCZ696 is superior to ARB alone in improving functional MR in patients
      with LV dysfunction and functional MR.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Functional ischemic mitral regurgitation (MR) has been reported to occur in up to 40% of
      patients after myocardial infarction, and the prevalence of functional MR is likely to
      increase with an aging population and improved survival rates for myocardial infarction. The
      presence of functional MR is associated with an increased incidence of heart failure and
      death, and patients with significant functional MR incur about a two-fold increase in the
      risk of mortality and about a four-fold increase in the risk of heart failure. Functional MR
      is caused by adverse left ventricular remodeling after myocardial injury with enlargement of
      the left ventricle (LV), apical and lateral displacement of papillary muscles, leaflet
      tethering and reduced closing forces. The leaflets are normal in secondary functional MR and
      the treatment is considerably different between functional and primary MR. Surgery is the
      only definitive therapy for primary severe MR and primary MR can usually be cured by surgical
      valve repair. However, surgical indications are unclear in severe functional MR, because
      outcomes after surgery for functional MR remain suboptimum. Operative mortality, long-term
      mortality and heart failure rates are still high in patients with severe functional MR
      despite surgical improvements. According to the current guidelines, mitral valve surgery may
      be considered only for severely symptomatic patients with severe secondary functional MR who
      have persistent symptoms despite optimal medical therapy for heart failure.

      Because secondary functional MR usually develops as a result of LV dysfunction, diuretics,
      beta blockers, angiotensin-converting-enzyme (ACE) inhibitors or angiotensin receptor
      blockers (ARB), and aldosterone antagonists are given to patients with functional MR in line
      with the guidelines in the management of heart failure. However, functional MR appears to
      remain common despite use of these drugs and current medical treatment is usually
      insufficient for reducing MR or reversing the adverse LV remodeling. Persistence of
      functional MR due to the insufficient effectiveness of current medical treatment
      significantly increases morbidity and mortality, and compared with surgical or percutaneous
      revascularization, significantly higher mortality was observed in patients managed with
      medical therapy.

      Quantitative assessment of MR is strongly recommended in the guidelines and the regurgitant
      volume and the effective regurgitant orifice area (EROA) of MR can be measured accurately and
      reproducibly by Doppler echocardiography. The EROA of MR has an important prognostic value in
      primary and secondary functional MR. Because functional MR carries an adverse prognosis with
      a graded relationship between MR severity and reduced survival, therapies that induce
      beneficial reverse remodeling of the LV and reduce MR, may improve survival. ACE inhibitors
      and ARBs could partially attenuate LV dilatation and remodeling after myocardial injury, but
      there are no published data from prospective trials regarding whether attenuation of
      remodeling by ACE inhibitors or ARBs reduces functional MR.

      LCZ696 is a dual-acting inhibitor of the renin-angiotensin-aldosterone system (RAAS) and
      neutral endopeptidase (NEP). As LCZ696 offers the therapeutic advantages of concomitantly
      blocking both RAAS and NEP, LCZ696 was more effective in reducing the risk of death from
      cardiovascular causes or hospitalization for heart failure in patients with chronic heart
      failure than ACE inhibitor. Because NEP is involved in the metabolism of a number of
      vasoactive peptides such as natriuretic peptides, NEP inhibitor has vasodilating effects,
      facilitates sodium excretion and has profound effects on LV remodeling. Trials of
      hypertension and heart failure with a preserved ejection fraction also showed that LCZ696 had
      greater hemodynamic and neurohormonal effects than ARB alone. To date, there has been no
      proven pharmacological therapy to improve functional MR, and the development of medical
      therapy should be at the forefront of research considering the limited role of surgery in
      managing functional MR. Investigators hypothesize that LCZ696 is superior to ARB alone in
      improving functional MR in patients with LV dysfunction and functional MR via synergistic
      effects of NEP and RAAS inhibition on LV remodeling, and try to examine this hypothesis in a
      multicenter, double-blind, randomized comparison study using echocardiography.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 2016</start_date>
  <completion_date type="Actual">January 2, 2018</completion_date>
  <primary_completion_date type="Actual">January 2, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of effective regurgitant orifice area (EROA) of functional mitral regurgitation from baseline to 12 months follow-up</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of regurgitant volume from baseline to 12 months follow-up</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of left ventricular end-systolic volume from baseline to 12 months follow-up</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of left ventricular end-diastolic volume from baseline to 12 months follow-up</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of incomplete mitral leaflet closure area from baseline to 12 months follow-up</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">118</enrollment>
  <condition>Mitral Valve Insufficiency</condition>
  <condition>Left Ventricular Dysfunction</condition>
  <arm_group>
    <arm_group_label>LCZ696</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LCZ696 for 12 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Valsartan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Valsartan for 12 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LCZ696</intervention_name>
    <arm_group_label>LCZ696</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valsartan</intervention_name>
    <arm_group_label>Valsartan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients must agree to the study protocol and provide written informed consent

          2. Outpatients â‰¥ 20 years of age, male or female

          3. Patients with secondary functional MR (stage B and C) and LV dysfunction

               -  Symptoms due to coronary ischemia or heart failure may be present but symptoms
                  due to MR should be absent

               -  Normal mitral valve leaflets and chords

               -  Regional or global wall motion abnormalities with mild or severe tethering of
                  leaflet

               -  ERO &gt; 0.10 cm2

               -  25% &lt; LV ejection fraction &lt; 50%

          4. Dyspnea of NYHA functional class II or III

          5. Patients must be on stable, optimized dose of an ACE inhibitors or ARBs for at least 4
             weeks prior to study entry

        Exclusion Criteria:

          1. History of hypersensitivity or allergy to the study drug, drugs of similar chemical
             classes, ARBs, or NEP inhibitors as well as known or suspected contraindications to
             the study drug

          2. Known history of angioedema

          3. Any evidence of structural mitral valve disease, including prolapse of mitral leaflets
             and rupture of chords or papillary muscles

          4. Current acute decompensated heart failure or dyspnea of NYHA functional class IV

          5. Medical history of hospitalization within 6 weeks

          6. Symptomatic hypotension and/or a SBP &lt; 100 mmHg at screening

          7. Estimated GFR &lt; 30 mL/min/1.73m2

          8. Serum potassium &gt; 5 mmol/L at screening

          9. Evidence of hepatic disease as determined by any one of the following: AST or ALT
             values exceeding 2 x upper limit of normal (ULN) at screening visit (Visit 0), history
             of hepatic encephalopathy, history of esophageal varices, or history of portacaval
             shunt

         10. Acute coronary syndrome, stroke, major CV surgery, PCI within 3 months

         11. Planned coronary revascularization or mitral valve intervention within 1 year

         12. Heart transplantation or implantation of cardiac resynchronization therapy

         13. History of severe pulmonary disease

         14. Significant aortic valve disease

         15. Primary aldosteronism

         16. Women of child-bearing potential, defined as all women physiologically capable of
             becoming pregnant, unless they are using a barrier method plus a hormonal method

         17. Pregnant or nursing (lactating) women

         18. Any clinically significant abnormality identified at the screening visit, physical
             examination, laboratory tests, or electrocardiogram which, in the judgment of the
             investigator, would preclude safe completion of the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Duk-Hyun Kang, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Inha University Hospital</name>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yonsei University Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 17, 2016</study_first_submitted>
  <study_first_submitted_qc>February 17, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 22, 2016</study_first_posted>
  <last_update_submitted>January 8, 2018</last_update_submitted>
  <last_update_submitted_qc>January 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>Duk-Hyun Kang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Functional Mitral Regurgitation</keyword>
  <keyword>Ischemic Mitral Regurgitation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ventricular Dysfunction</mesh_term>
    <mesh_term>Mitral Valve Insufficiency</mesh_term>
    <mesh_term>Ventricular Dysfunction, Left</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valsartan</mesh_term>
    <mesh_term>LCZ 696</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

